Donald Mahler, CHEST 2021: Precision Medicine in COPD

We were delighted to speak with Prof. Donald Mahler (Geisel School of Medicine, Dartmouth, NH, USA) to explore his presentation ‘Precision Medicine in COPD’, which was presented at CHEST 2021, 17-20 October 2021. Questions What is the limitation of traditional approaches to the treatment of COPD? (0:26) What are the major challenges of moving to […]

Rohit Gupta, CHEST 2021: Updates in Sarcoidosis

We were delighted to talk with Prof. Rohit Gupta (Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA) around his presentation ‘Making Progress in the Field Of Sarcoidosis: Time to Move Forward’, which was presented at CHEST 2021, 17-20 October 2021. Questions What are the major challenges in the diagnosis of people with sarcoidosis? […]

David Fleischer: Updates in Peanut Allergy Treatment

TouchRESPIRATORY got the opportunity to catch up with Dr. David Fleischer (Children’s Hospital Colorado, Aurora, CO, USA) to discuss the current available therapies and future of the treatment paradigm for peanut allergy. Questions How has the approval of Palforzia impacted the treatment paradigm for peanut allergies? (0:14) What questions remain unanswered regarding oral immunotherapies and […]

Doreen J. Addrizzo-Harris: Highlights from CHEST 2021

We had the absolute pleasure to meet with President-Designate of CHEST, Professor Doreen J. Addrizzo-Harris (NYU Grossman School of Medicine, New York, NY, USA) who gave us some of the key highlights from this year’s annual meeting of CHEST, 17-20 October 2021. Questions What were your personal highlights of CHEST 2021? (0:34) How has CHEST […]

Dupilumab—A Potential New Biologic for Chronic Rhinosinusitis with Nasal Polyps

US Respiratory & Pulmonary Diseases. 2020;5(1):15-7 DOI: https://doi.org/10.17925/USPRD.2020.5.1.15

Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]

Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease

US Respiratory and Pulmonary Diseases. 2020;5(1):28-32 DOI: https://doi.org/10.17925/USPRD.2020.5.1.28

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis of the skin and other organs. It has a range of clinical manifestations, and the typical internal organs involved include the lungs, kidneys, heart, and gastrointestinal tract. Though it is an uncommon condition, the mortality rate of this disease is higher than any […]

Nirsevimab: An Extended Half-life Monoclonal Antibody for the Prevention of Infant Respiratory Syncytial Virus Infection

touchREVIEWS in Respiratory & Pulmonary Medicine. 2021;6(1):Online ahead of publication

Respiratory syncytial virus (RSV) is a ubiquitous virus that causes annual epidemics of infection in young children in all parts of the world. In temperate regions, epidemics are seasonal, and predictable during the winter months. Approximately half of all infants develop their first RSV infection prior to their first birthday. By 24 months of age, […]

Sleep Disorders in Neuromuscular Diseases: Adaption in Care Provision During the COVID-19 Pandemic

touchREVIEWS in Respiratory & Pulmonary Medicine. 2021;6(1):Online ahead of journal publication

Sleep disturbances are exceedingly common and potentially morbid in patients with neuromuscular diseases (NMD).1 A constellation of physiologic changes occur in patients with NMDs which, in concert with normal physiologic changes during sleep, lead to decreased nocturnal ventilation that often precedes daytime hypoventilation. The standard manner in which we diagnose and treat sleep disorders in this […]